Introduction
============

Endometriosis (EMs), characterized by the growth of endometrium-type tissue outside the uterine cavity, is a common and usually chronic (long-term) inflammatory disorder, affecting 5--10% of women in their reproductive years ([@ref-49]). EMs is also considered as a phenotypically heterogeneous condition not only due to diverse symptoms, such as infertility, pelvic pain or dysmenorrhea but also different lesion locations, predominantly but not exclusively, in the pelvic compartment ([@ref-42]). Since the classic retrograde menstruation hypothesis ([@ref-35]) that during menstrual uterine contractions, endometrial fragments via trans-tubal reflux flowed to implant onto the peritoneum and abdominal organs could not explain the fact that 76--90% of women experienced retrograde menstruation but not all of these women suffered from EMs ([@ref-3]), there must exist other mechanisms facilitating the development of EMs. On the other hand, as early as 1997, Nisolle and Donnez provided morphological and histochemical evidence indicating that three main subtypes of endometriosis: ovarian endometriosis (OE), peritoneal endometriosis (PE), and deep infiltrating endometriosis (DIE), should be considered different entities, though they shared the histologic features of endometrial glands and stroma ([@ref-29]). Thus, investigating the common and specific mechanisms among different EMs subtypes may provide new insight into the pathogenesis of endometriosis. However, due to the limited information as well as samples available from single cohorts, few integrative analyses of EMs subtypes were conducted.

Therefore, in this article, we analyzed the microarray datasets [GSE7305](GSE7305) and [GSE7307](GSE7307) of OE, [E-MTAB-694](E-MTAB-694) of PE, and [GSE25628](GSE25628) of DIE to obtain common differentially expressed genes (DEGs) among three EMs subtypes along with specific DEGs in each subtype by comparing ectopic lesions (EC) with eutopic endometrium (EU) from EMs patients. Then, the Kyoto Encyclopedia of Genes (KEGG), protein-protein interaction (PPI) network and validation analysis were performed to analyze these common and specific DEGs ([Fig. 1](#fig-1){ref-type="fig"}). Overall, all results were combined to promote further understanding of different EMs subtypes and reveal a more thorough landscape of EMs.

![The flowchart of integrative analysis of microarray datasets from three different endometriosis subtypes.\
Abbreviations: OE, ovarian endometriosis; PE, peritoneal endometriosis; DIE, deep infiltering endometriosis; DEGs, differentially expressed genes; KEGG, KyotoEncyclopedia of Genes; PPI, protein-protein interaction.](peerj-08-8730-g001){#fig-1}

Materials & Methods
===================

Data resources
--------------

The search for endometriosis-related microarray datasets was conducted in two public databases: Gene Expression Omnibus (<https://www.ncbi.nlm.nih.gov/geo/>) and Array-Express (<https://www.ebi.ac.uk/ar-rayexpress/>). The keywords: 'endometriosis', 'endometrium', 'tissue', 'homo sapiens' or 'human' respectively with 'ovarian', 'peritoneal', 'DIE', 'deep' or 'infiltrating' were employed to mine the datasets for three EMs subtypes. Additionally, all selected datasets were based on Affymetrix platforms to reduce the 'platform effect' due to different probe designs among different companies. Finally, four datasets were included: [GSE7305](GSE7305) and [GSE7307](GSE7307) for OE, [E-MTAB-694](E-MTAB-694) for PE, and [GSE25628](GSE25628) for DIE ([Table 1](#table-1){ref-type="table"}), all of which contained at least 8 samples for both ectopic lesions (EC) and eutopic endometrium (EU) from the EMs patients. A total of 54 EC samples from these datasets of different EMs subtypes and 58 EU samples were included.

10.7717/peerj.8730/table-1

###### Basic information of the microarray datasets of three different EMs subtypes.
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  **Subtype**   **Accession**              **Platform**                           **No. of probes**   **No. of samples (EU/EC, whether paired)**   **Tissue stage**                                **References**
  ------------- -------------------------- -------------------------------------- ------------------- -------------------------------------------- ----------------------------------------------- ----------------
  OE            [GSE7305](GSE7305)         [GPL570](GPL570) \[HG-U133_Plus_2\]    54,675              20 (10/10, paired)                           2 Follicular phases and 8 Luteal phases         [@ref-14]
                [GSE7307](GSE7307)         [GPL570](GPL570) \[HG-U133_Plus_2\]    54,675              41 (23/18, unknown)                          Unpublished                                     Unpublished
  PE            [E-MTAB-694](E-MTAB-694)   [GPL570](GPL570): \[HG-U133_Plus_2\]   54,675              35 (17/18, most were paired)                 8 Proliferative phases and 9 Secretory phases   [@ref-37]
  DIE           [GSE25268](GSE25268)       [GPL571](GPL571): \[HG-U133A_2\]       22,277              16 (08/08, paired)                           16 Proliferative phases                         [@ref-8]

**Notes.**

EMsendometriosisOEovarian endometriosisPEperitoneal endometriosisDIEdeep infiltrating endometriosisEUeutopic endometriumECectopic lesions

Besides, all EC and EU samples in [GSE7305](GSE7305) and [GSE25628](GSE25628), as well as most in [E-MTAB-694](E-MTAB-694), were paired, meaning they were obtained from the same patients. The information on patients' clinical characteristics in [E-MTAB-694](E-MTAB-694) for PE and [GSE25628](GSE25628) for DIE were provided in the [Tables S1](#supp-1){ref-type="supplementary-material"} and [S2](#supp-2){ref-type="supplementary-material"} according to the original articles ([@ref-8]; [@ref-37]). However, the clinical information of patients was unavailable in the two datasets for OE: [GSE7305](GSE7305) (not provided by the original article ([@ref-14])) and [GSE7307](GSE7307) (not originally published). Since our analysis did not involve any experiment on humans or animals directly, ethical approval was not necessary.

Data preprocessing
------------------

The raw data CEL files and group information of four datasets were downloaded from the GEO and Array-Express database. Firstly, the CEL files of [GSE7305](GSE7305) and [GSE7307](GSE7307) of subtype OE were combined into an integrated dataset, which was subsequently named the 'merged OE dataset'. Then, CEL files of this 'merged OE dataset' as well as the individual PE dataset [E-MTAB-694](E-MTAB-694) and DIE dataset [GSE25628](GSE25628) were read by 'Affy' R package ([@ref-10]), and further processed by the robust multi-array average (RMA) method for background correction, normalization, and expression calculation ([@ref-16]). Moreover, the 'ComBat' function in the SVA R package ([@ref-25]) was utilized to adjust the batch effects in the merged OE dataset, and then the principal component analysis (PCA) was applied to assess the performance of the batch effect adjustment. Also, the individual PE and DIE datasets were performed with PCA analysis to visualize sample distributions. Furthermore, probes were annotated according to the annotation files provided by Affymetrix official website (<http://www.affymetrix.com/>), and unmatched probes were abandoned.

Identification of DEGs
----------------------

After pretreatment, R package limma ([@ref-33]) was applied to filtrate DEGs of these three datasets: the merged OE dataset of [GSE7305](GSE7305) and [GSE7307](GSE7307), the individual PE dataset [E-MTAB-694](E-MTAB-694) and DIE dataset [GSE25628](GSE25628), respectively, with the cutoff criteria: ---log~2~ fold change (FC)---\>1 and *p*-value \<0.05. Additionally, the intersection analysis was conducted among three sets of DEGs.

KEGG pathway enrichment analysis
--------------------------------

To explain common pathogenesis among three EMs subtypes (OE, PE, and DIE), KEGG pathway enrichment analysis of shared DEGs among the merged OE dataset of [GSE7305](GSE7305) and [GSE7307](GSE7307), the individual PE dataset [E-MTAB-694](E-MTAB-694) and DIE dataset [GSE25628](GSE25628) was performed by DAVID (<http://david.abcc.ncifcrf.gov/>), an online tool for comprehensive functional annotation of genes and proteins. Furthermore, to explore specific pathogenesis of these three subtypes, specific DEGs in each dataset were also conducted with KEGG pathway enrichment analyses by DAVID. A threshold of *p*-value \<0.05 was utilized to filter all KEGG pathways, which were also ranked by the *p*-value.

Validation of interested pathway-related genes in [GSE105764](GSE105764)
------------------------------------------------------------------------

Considering all training datasets were comprised of microarray data, we intended to validate interested pathways related genes, for example, the most enriched pathway of common DEGs or representative pathways in the certain subtype, in RNA-sequencing datasets. However, due to the lack of PE and DIE RNA-sequencing datasets in searching results, we only performed the validation analysis in an OE RNA-sequencing dataset [GSE105764](GSE105764) from the GEO database, which contained 8 paired EC and EU tissue samples based on [GPL20301](GPL20301) (Illumina HiSeq 4000) ([@ref-48]). The raw read counts were calculated by the DEseq2 R package ([@ref-27]) to obtain the DEGs. Additionally, we also listed the expression of selected genes in the previously analyzed results of microarray datasets as a comparison.

PPI networks construction and identification of hub DEGs
--------------------------------------------------------

The identified common DEGs among three EMs subtypes were uploaded to the online database STRING (<http://string-db.org/>; version 11.0) to explore their interactions at the protein level, with an interaction score \>0.4 as the cutoff value. Afterward, the PPI network was visualized in software Cytoscape (version 3.6.1) and analyzed by the 'Degree method' in plugin Cytohubba to identify the top 5 hub nodes in the network.

Validation analysis of hub DEGs in [GSE105764](GSE105764)
---------------------------------------------------------

We also performed the validation analysis of the top 5 hub DEGs identified from the PPI network constructed of 148 common DEGs among three EMs subtypes in the OE RNA-sequencing dataset [GSE105764](GSE105764). Additionally, we also listed the expression of these hub genes in the previously analyzed results of microarray datasets as a comparison.

Results
=======

Data preprocessing and Identification of DEGs
---------------------------------------------

After combing the expression data, the merged OE dataset of [GSE7305](GSE7305) and [GSE7307](GSE7307) included 33 EU and 28 ovarian EC samples. Besides, the individual PE dataset [E-MTAB-694](E-MTAB-694) contained 17 EU and 18 peritoneal EC samples, and the individual DIE dataset [GSE25628](GSE25628) comprised 8 EU and 8 deep infiltrating EC samples. After normalization of raw data in these datasets, boxplots were depicted, showing even mean values of gene expression in each sample. ([Fig. S1](#supp-5){ref-type="supplementary-material"}). Moreover, the principal component analysis (PCA) was performed to examine the differences between EC and EU groups ([Figs. 2A](#fig-2){ref-type="fig"}, [2B](#fig-2){ref-type="fig"} and [2C](#fig-2){ref-type="fig"}).

![Principal component analysis (PCA) and identification of differentially expressed genes (DEGs) in each EMs subtype dataset.\
(A), (B), (C) After normalization of raw data in the merged OE dataset of [GSE7305](GSE7305) and [GSE7307](GSE7307), the individual PE dataset [E-MTAB-694](E-MTAB-694) and the DIE dataset [GSE25628](GSE25628), the principal component analysis (PCA) was performed to examine the differences between EC and EU groups; (D), (E), (F) Volcano plots of the distributions of DEGs between EC and EU in the merged OE dataset of [GSE7305](GSE7305) and [GSE7307](GSE7307), the individual PE dataset [E-MTAB-694](E-MTAB-694) and the DIE dataset [GSE25628](GSE25628). DEGs with log~2~FC \>1 were shown in red dots; DEGs with log~2~FC \< − 1 were in green dots (*P* \< 0.05). No significantly changed genes are marked as black dots. EMs, endometriosis; OE, ovarian endometriosis; PE, peritoneal endometriosis; DIE, deep infiltrating endometriosis; EC, ectopic lesions; EU, eutopic endometrium; log~2~FC, log~2~ Fold Change.](peerj-08-8730-g002){#fig-2}

Subsequently, analyzed by the R package limma ([@ref-33]) with the threshold of ---log~2~ FC--- \>1 and *p*-value \<0.05, a total of 744 upregulated as well as 626 downregulated DEGs were obtained from the merged OE dataset of [GSE7305](GSE7305) and [GSE7307](GSE7307), along with 731 upregulated and 772 downregulated DEGs from the individual PE dataset [E-MTAB-694](E-MTAB-694), and 268 upregulated and 77 downregulated DEGs from the individual DIE dataset [GSE25628](GSE25628). Volcano plots were depicted for the visualization of DEGs in each dataset ([Figs. 2D](#fig-2){ref-type="fig"}, [2E](#fig-2){ref-type="fig"} and [2F](#fig-2){ref-type="fig"}). The intersection analysis indicated that 148 genes were common to three datasets, 729 DEGs specific to the merged OE dataset, 777 DEGs specific to the individual PE dataset and only 36 DEGs specific to the individual DIE dataset owing to relatively fewer probes in this dataset, as shown in the Venn diagram ([Fig. 3A](#fig-3){ref-type="fig"}).

![Intersection analysis and KEGG pathway enrichment analysis of common and specific DEGs among OE, PE, and DIE.\
(A) Venn diagram of DEGs selected with ---log~2~FC---\>1 and *p*-value \< 0.05 from the merged OE dataset of [GSE7305](GSE7305) and [GSE7307](GSE7307), the individual PE dataset [E-MTAB-694](E-MTAB-694) and the individual DIE dataset [GSE25628](GSE25628). These three datasets showed an overlap of 148 genes; (B) significantly enriched KEGG pathways of 148 shared DEGs; (C) significantly enriched KEGG pathways of 729 DEGs specific to the merged OE dataset of [GSE7305](GSE7305) and [GSE7307](GSE7307); (D) significantly enriched KEGG pathways of 777 DEGs specific to the individual PE dataset [E-MTAB-694](E-MTAB-694); (E) significantly enriched KEGG pathways of 36 DEGs specific to the individual DIE dataset [GSE25628](GSE25628). All the entries were screened out with the *p*-value \<0.05 and ranked by *p*-value.](peerj-08-8730-g003){#fig-3}

KEGG enrichment analysis of common and specific DEGs
----------------------------------------------------

Based on the KEGG analysis from the online tool DAVID, 148 common DEGs were mainly enriched in the pathways of arachidonic acid (AA) metabolism, vascular smooth muscle contraction, drug metabolism-cytochrome P450, complement and coagulation cascades, tyrosine metabolism, according to the *p*-value ranking ([Fig. 3B](#fig-3){ref-type="fig"}).

10.7717/peerj.8730/table-2

###### The top five enriched KEGG pathways of common DEGs among three EMs subtypes datasets and specific DEGs in each EMs subtype dataset.
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  **Category of DEGs**                                                                                                                                                                    **KEGG ID**                                 **Pathway description**                  **Count**     ***P*-value**                                                                                                                                                                                                                **Enriched Genes**
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------- ---------------------------------------- ------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------
  **148 common DEGs among the merged OE dataset of [GSE7305](GSE7305) and [GSE7307](GSE7307), the individual PE dataset [E-MTAB-694](E-MTAB-694) and DIE dataset [GSE25628](GSE25628)**   hsa00590                                    Arachidonic acid metabolism              4             0.023854965                                                                                                                                                                                                                  GGT5, CYP2J2, PTGIS, PLA2G2A
  hsa04270                                                                                                                                                                                Vascular smooth muscle contraction          5                                        0.030857192   ACTG2, AGTR1, ACTA2, PLA2G2A, MYL9                                                                                                                                                                                           
  hsa00982                                                                                                                                                                                Drug metabolism - cytochrome P450           4                                        0.031595883   FMO1, FMO2, AOX1, ADH1B                                                                                                                                                                                                      
  hsa04610                                                                                                                                                                                Complement and coagulation cascades         4                                        0.032797081   C7, THBD, C3, CFH                                                                                                                                                                                                            
  hsa00350                                                                                                                                                                                Tyrosine metabolism                         3                                        0.048956335   AOX1, ADH1B, AOC3                                                                                                                                                                                                            
  **729 specific DEGs in the merged OE dataset of [GSE7305](GSE7305) and [GSE7307](GSE7307)**                                                                                             hsa05150                                    Staphylococcus aureus infection          14            2.19096E-07                                                                                                                                                                                                                  HLA-DQB1, ICAM1, C3AR1, C5AR1, MASP1, CFB, C1R, ITGB2, C1S, C1QC, HLA-DQA1, FCGR2C, FCGR2A, C2
  hsa04151                                                                                                                                                                                PI3K-Akt signaling pathway                  32                                       4.06007E-05   FGFR2, FGFR3, OSMR, FGF9, TNC, ITGA11, FGF13, KIT, LPAR1, ITGB8, IL4R, COL27A1, PIK3AP1, ANGPT1, GNG2, GNG4, THBS1, COL11A1, INSR, PPP2R2C, PIK3R1, FN1, MET, NR4A1, IGF1, CCND1, CDKN1A, ITGA6, PRLR, VEGFA, PDGFRA, JAK3   
  hsa04913                                                                                                                                                                                Ovarian steroidogenesis                     10                                       0.00016359    CYP17A1, PLA2G4A, PTGS2, CYP11A1, STAR, IGF1, SCARB1, ALOX5, INSR, BMP6                                                                                                                                                      
  hsa04015                                                                                                                                                                                Rap1 signaling pathway                      22                                       0.000172943   FGFR2, FGFR3, FGF9, MET, SIPA1L2, IGF1, ITGB2, FGF13, LPAR1, KIT, DOCK4, RASSF5, PLCB4, ID1, VEGFA, PDGFRA, RAPGEF5, ANGPT1, THBS1, PLCB1, INSR, PIK3R1                                                                      
  hsa04514                                                                                                                                                                                Cell adhesion molecules (CAMs)              17                                       0.00026996    HLA-DQB1, ICAM1, PTPRC, MAG, CLDN4, CADM1, ITGB2, CLDN11, CDH3, HLA-DQA1, CD86, ITGA6, ITGB8, CNTN1, CNTNAP2, VCAN, JAM3                                                                                                     
  **777 specific DEGs in the individual PE dataset [E-MTAB-694](E-MTAB-694)**                                                                                                             hsa04060                                    Cytokine-cytokine receptor interaction   21            0.002513955                                                                                                                                                                                                                  CXCL1, TNFRSF21, IL2RB, CSF1, CXCL3, IL19, LIFR, CD40, CCL4, LEP, LIF, CCL13, TNFRSF10B, PPBP, CCL20, CXCR4, CCR2, TNFRSF18, CSF2RB, BMPR1B, CSF1R
  hsa04514                                                                                                                                                                                Cell adhesion molecules (CAMs)              14                                       0.005814763   F11R, NRXN3, SELL, ICAM2, L1CAM, CD40, ITGA4, HLA-E, CDH5, SIGLEC1, SDC1, CLDN1, ESAM, CD28                                                                                                                                  
  hsa04670                                                                                                                                                                                Leukocyte transendothelial migration        12                                       0.00786069    F11R, EZR, VAV3, CXCR4, MAPK13, CLDN1, ESAM, TXK, ITGA4, CDH5, PRKCB, VCL                                                                                                                                                    
  hsa04923                                                                                                                                                                                Regulation of lipolysis in adipocytes       8                                        0.007916063   ADCY4, ADRB2, PLIN1, ADCY5, NPY1R, PRKG1, TSHR, LIPE                                                                                                                                                                         
  hsa04650                                                                                                                                                                                Natural killer cell-mediated cytotoxicity   11                                       0.029482747   CD48, PRF1, VAV3, TNFRSF10B, ICAM2, KIR2DS2, GZMB, KIR2DL3, KIR2DL2, KIR2DL4, PRKCB                                                                                                                                          
  **36 specific DEGs in the individual DIE dataset [GSE25628](GSE25628)**                                                                                                                 hsa05200                                    Pathways in cancer                       5             0.013783298                                                                                                                                                                                                                  COL4A3, PTGER3, COL4A6, RAD51, F2R
  hsa05146                                                                                                                                                                                Amoebiasis                                  3                                        0.027515834   COL4A3, ARG2, COL4A6                                                                                                                                                                                                         

**Notes.**

KEGGKyoto Encyclopedia of GenesDEGsdifferentially expressed genesEMsendometriosisOEovarian endometriosisPEperitoneal endometriosisDIEdeep infiltrating endometriosis

Likewise analyzed by DAVID, KEGG analysis showed that the top5 significantly enriched pathways of 729 specific DEGs in the merged OE dataset of [GSE7305](GSE7305) and [GSE7307](GSE7307) were staphylococcus aureus infection, PI3K-Akt signaling pathway, ovarian steroidogenesis, Rap1 signaling pathway, and cell adhesion molecules (CAMs) ([Fig. 3C](#fig-3){ref-type="fig"}); the top5 significantly enriched pathways of 777 specific DEGs in the individual PE dataset [E-MTAB-694](E-MTAB-694) were cytokine-cytokine receptor interaction, cell adhesion molecules (CAMs), leukocyte trans-endothelial migration, regulation of lipolysis in adipocytes, and natural killer cell-mediated cytotoxicity ([Fig. 3D](#fig-3){ref-type="fig"}); 36 specific DEGs in the individual DIE dataset [GSE25628](GSE25628) were only enriched in two pathways: pathways in cancer and amoebiasis ([Fig. 3E](#fig-3){ref-type="fig"}). Furthermore, the above-mentioned significant enriched pathways related genes were detailed in [Table 2](#table-2){ref-type="table"}.

Validation of interested pathway-related genes in [GSE105764](GSE105764)
------------------------------------------------------------------------

Since endometriosis was defined as an inflammatory disorder ([@ref-4]) and the top 1 enriched pathway of 148 common DEGs was the arachidonic acid (AA) metabolism pathway, a key pro-inflammatory pathway ([@ref-24]), we validated this pathway-related genes: GGT5, CYP2J2, PTGIS and PLA2G2A in the OE RNA-sequencing dataset [GSE105764](GSE105764). The consistency results between microarray training datasets and the RNA-sequencing validation dataset showed that most of these genes were found to be significantly higher in EC tissue than EU endometrium, except for CYP2J2 ([Table 3](#table-3){ref-type="table"}).

10.7717/peerj.8730/table-3

###### The expression of the arachidonic acid metabolism pathway-related genes in microarray training datasets and the OE RNA-sequencing validation dataset [GSE105764](GSE105764).

![](peerj-08-8730-g007)

  **Gene Symbol**   **Gene Description**                            **OE RNA-sequencing dataset [GSE105764](GSE105764)**   **The merged OE dataset of [GSE7305](GSE7305) and [GSE7307](GSE7307)**   **The individual PE dataset [E-MTAB-694](E-MTAB-694)**   **The individual DIE dataset [GSE25628](GSE25628)**                                               
  ----------------- ----------------------------------------------- ------------------------------------------------------ ------------------------------------------------------------------------ -------------------------------------------------------- ----------------------------------------------------- -------------- ------------- -------------- -------------
  PTGIS             Prostaglandin I2 Synthase                       6.289598638                                            2.43946E-44                                                              4.631282825                                              2.91622E-16                                           4.971203942    1.20213E-16   3.508766958    0.002253242
  PLA2G2A           Phospholipase A2 Group IIA                      2.822326237                                            0.001074114                                                              4.849610555                                              2.38055E-25                                           3.551202751    3.01372E-06   3.152761244    0.010549907
  GGT5              Gamma-Glutamyltransferase 5                     2.682418539                                            1.54252E-12                                                              1.03319199                                               1.421E-13                                             1.031785388    5.90453E-07   1.32309443     0.006376396
  CYP2J2            Cytochrome P450 Family 2 Subfamily J Member 2   −6.239846138                                           1.75094E-27                                                              −1.142837781                                             1.79003E-09                                           −1.850912918   9.66805E-09   −1.160485084   0.02902089

**Notes.**

Log2 FCLog2 fold changeOEovarian endometriosisPEperitoneal endometriosisDIEdeep infiltrating endometriosis

Moreover, besides the common pathogenetic pathways, each different subtype of EMs might possess its peculiar molecular signature. Since the validation dataset [GSE105764](GSE105764) was an OE dataset and the inflammation in EMs were driven by estradiol ([@ref-4]), we chose ovarian steroidogenesis---one representative pathway in subtype OE related genes to validate. The validation results showed that most genes in this pathway were significantly overexpressed in EC in subtype OE, almost consistent with that in the OE microarray training dataset, whereas with no significant difference between EU and EC in the individual PIE and DIE dataset ([Table 4](#table-4){ref-type="table"}), which suggested ectopic tissue specificity and focal prominent aberrant hormonal environment in OE.

10.7717/peerj.8730/table-4

###### The expression of one representative pathway in subtype OE--ovarian steroidogenesis related genes in microarray training datasets and the OE RNA-sequencing validation dataset [GSE105764](GSE105764).

![](peerj-08-8730-g008)

  **Gene Symbol**   **Gene Description**                             **OE RNA-sequencing dataset [GSE105764](GSE105764)**   **The merged OE dataset of [GSE7305](GSE7305) and [GSE7307](GSE7307)**   **The individual PE dataset [E-MTAB-694](E-MTAB-694)**   **The individual DIE dataset [GSE25628](GSE25628)**                                                          
  ----------------- ------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------------------------ -------------------------------------------------------- ----------------------------------------------------- -------------------------- ------------- ------------- -------------
  STAR              Steroidogenic Acute Regulatory Protein           3.844497923                                            3.67398E-10                                                              5.549409967                                              5.35385E-30                                           −0.691371832               0.030315396   0.2446853     0.854991
  BMP6              Bone Morphogenetic Protein 6                     2.585401261                                            9.63142E-08                                                              2.13686869                                               3.12026E-22                                           0.16812685                 0.530786767   0.3323532     0.5156626
  CYP11A1           Cytochrome P450 Family 11 Subfamily A Member 1   2.571939702                                            3.06172E-11                                                              1.977665697                                              1.63051E-09                                           −0.074703419 0.584259769   −0.3281747    0.7447965     
  SCARB1            Scavenger Receptor Class B Member 1              2.264263509                                            2.98276E-21                                                              1.74100742                                               1.5326E-11                                            0.163414061                0.342902499   0.06680135    0.9171244
  ALOX5             Arachidonate 5-Lipoxygenase                      1.932324569                                            2.01964E-06                                                              1.113589966                                              2.23627E-05                                           −0.030632071               0.87312448    0.2211488     0.7237545
  PTGS2             Prostaglandin-Endoperoxide Synthase 2            1.499535863                                            0.021110249                                                              1.188644849                                              0.000423004                                           −1.324453675 0.132193434   −0.1371545    0.8414268     
  CYP17A1           Cytochrome P450 Family 17 Subfamily A Member 1   1.418715737                                            0.004554443                                                              1.049381469                                              0.001851908                                           0.005875675                0.890819272   −0.03743256   0.9750525
  INSR              Insulin Receptor                                 0.381745388                                            0.192710241                                                              1.285645953                                              7.63097E-12                                           0.02287573                 0.938544186   0.387068073   0.208446551
  IGF1              Insulin Like Growth Factor 1                     −0.673337332                                           0.124361875                                                              −1.659370252                                             5.34224E-09                                           −0.646869143               0.0069179     −0.2747584    0.5370414
  PLA2G4A           Phospholipase A2 Group IVA                       −1.315828744                                           0.005668833                                                              −1.883142744                                             5.15085E-14                                           −0.051607453               0.816803637   0.1022455     0.8456387

**Notes.**

OEovarian endometriosisPEperitoneal endometriosisDIEdeep infiltrating endometriosisLog2 FCLog2 fold change

We also noticed that both specific DEGs in OE and DIE were enriched in the pathways in cancer, though enriched genes were different. The enriched genes in the 'pathways in cancer' in DIE were COL4A3, COL4A6, PTGER3, RAD51, F2R, while OE seems to be associated with 'pathways in cancer' mainly by PI3K-Akt signaling pathway-related genes, such as FN1, GNG2, KIT, PTGS2, PDGFRA, LPAR1, CCND1, ITGA6, FGFR3, VEGFA, PIK3R1, FGFR2, MET, indicated by both microarray training datasets and RNA-sequencing validation dataset ([Tables S3](#supp-3){ref-type="supplementary-material"} and [S4](#supp-4){ref-type="supplementary-material"}).

PPI network construction and hub DEGs identification
----------------------------------------------------

By analyzing 148 common DEGs in database STRING, a PPI network with 99 nodes and 178 edges was constructed and then visualized in Cytoscape ([Fig. 4A](#fig-4){ref-type="fig"}). Furthermore, the top 5 hub nodes: CCNB1, CCNB2, RRM2, DTL, AURKB were identified from this PPI network by using the Degree method in plugin Cytohubba ([Fig. 4B](#fig-4){ref-type="fig"}).

Validation analysis of hub DEGs in [GSE105764](GSE105764)
---------------------------------------------------------

As shown in [Table 5](#table-5){ref-type="table"}, the expression trend of top 5 hub DEGs (CCNB1, CCNB2, RRM2, DTL, AURKB) was consistent in three subtypes---all under-expressed in ectopic lesions compared to eutopic endometrium, which was also further validated in the OE RNA-sequencing dataset [GSE105764](GSE105764).

![Protein-protein interaction (PPI) network construction and identification of hub nodes.\
(A) PPI network constructed by 148 shared DEGs among the merged OE dataset of [GSE7305](GSE7305) and [GSE7307](GSE7307), the individual PE dataset [E-MTAB-694](E-MTAB-694) and DIE dataset [GSE25628](GSE25628). The red nodes represent upregulated genes and the green nodes represent downregulated genes. (B) Top 5 hub nodes (CCNB1, RRM2, DTL, CCNB2, AURKB) identified from the PPI network by using the Degree method in plugin Cytohubba. The nodes color changes gradually from yellow to red in ascending order according to the Degree ranking.](peerj-08-8730-g004){#fig-4}

Discussion
==========

Endometriosis (EMs) was considered as a heterogeneous disease and its subtypes: ovarian endometriosis (OE), peritoneal endometriosis (PE), and deep infiltrating endometriosis (DIE) were likely to possess different aetiologies, which might require different diagnostic markers as well as treatments ([@ref-29]; [@ref-13]). However, it is rare to see that all these three EMs subtypes were simultaneously included and analyzed in one study. To our best of knowledge, our article represents the first endeavor to analyze the common and specific molecular signatures among OE, PE, and DIE in a bioinformatic way based on effective microarray or RNA-sequencing datasets.
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###### The expression of the top 5 hub genes identified from the PPI network in microarray training datasets and the OE RNA-sequencing validation dataset [GSE105764](GSE105764).

![](peerj-08-8730-g009)

  **Gene symbol**   **Gene description**                               **OE RNA-sequencing dataset [GSE105764](GSE105764)**   **The merged OE dataset of [GSE7305](GSE7305) and [GSE7307](GSE7307)**   **The individual PE dataset [E-MTAB-694](E-MTAB-694)**   **The individual DIE dataset [GSE25628](GSE25628)**                                               
  ----------------- -------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------------------------ -------------------------------------------------------- ----------------------------------------------------- -------------- ------------- -------------- -------------
  RRM2              Ribonucleotide Reductase Regulatory Subunit M2     −2.545059091                                           5.65568E-06                                                              −2.902398466                                             6.14787E-10                                           −3.521816066   1.01611E-08   −1.908309782   0.01636418
  AURKB             Aurora Kinase B                                    −2.311429822                                           3.34652E-05                                                              −1.42932862                                              3.39568E-09                                           −1.911232107   3.34734E-06   −1.0990377     0.039806461
  CCNB1             Cyclin B1                                          −1.856061436                                           5.54985E-05                                                              −2.207580173                                             3.967E-09                                             −2.161536326   3.96789E-06   −1.264483101   0.047858003
  CCNB2             Cyclin B2                                          −1.825733268                                           0.000537883                                                              −1.938433806                                             3.70498E-09                                           −2.689873382   7.46834E-07   −1.446885624   0.044121405
  DTL               Denticleless E3 Ubiquitin Protein Ligase Homolog   −1.228039999                                           0.003406252                                                              −1.757599775                                             1.88499E-08                                           −1.998898813   5.57114E-07   −1.372163345   0.032638654
                                                                                                                                                                                                                                                                                                                                                                  

**Notes.**

Log2 FCLog2 fold changeOEovarian endometriosisPEperitoneal endometriosisDIEdeep infiltrating endometriosis

In this article, we conducted an integrative analysis of EMs mRNA microarray datasets belonging to three different subtypes: [GSE7305](GSE7305) and [GSE7307](GSE7307) of OE, [E-MTAB-694](E-MTAB-694) of PE, and [GSE25628](GSE25628) of DIE. By analyzing DEGs between EU and EC samples, we found that 148 shared DEGs were common to three EMs subtypes, which were mainly involved in the pathways of arachidonic acid (AA) metabolism, vascular smooth muscle contraction, drug metabolism-cytochrome P450, complement and coagulation cascades, tyrosine metabolism revealed by KEGG enrichment analysis. Moreover, both the microarray training datasets and validation OE RNA-sequencing dataset showed that most of the genes in the top 1 enriched pathway---arachidonic acid (AA) metabolism pathway were activated in the EC tissues, except for CYP2J2.

In the arachidonic acid (AA) metabolism pathway, under the action of bioactive enzymes, substrate AA was catalyzed to generate endogenous eicosanoids such as prostaglandins (PGs), leukotrienes (LTs) and epoxyeicosatrienoic acids (EETs), which acted as mediators of various inflammatory disorders ([@ref-24]), including endometriosis ([@ref-2]; [@ref-28]; [@ref-34]). PLA2G2A, a member of the phospholipase A2 family (PLA2) to catalyze the release of AA from membrane phospholipids, had been reported over-expressed in OE ([@ref-20]), DIE ([@ref-6]) and PE ([@ref-26]) ectopic lesions compared to normal or eutopic endometrium. The increased levels of PLA2G2A in endometriotic tissue would be responsible for providing AA for further PGs biosynthesis, such as PGE2, thus potentiating survival, migration, and invasion of endometriotic cells ([@ref-1]). The overexpression of PTGIS, functioning to convert prostaglandin H2 (PGH2) to prostaglandin I2 (PGI2), whose higher expression in the peritoneal fluid was observed in patients with endometriosis ([@ref-45]), had also been found a previous study ([@ref-28]). Under hypoxic conditions, PTGIS was reported to promote VEGF expression in human lung fibroblasts by producing PGI2 ([@ref-44]), whose enhanced production in ovarian endometrial cyst seemed to be associated with dysmenorrhea in endometriosis patients ([@ref-21]). GGT5 was responsible for converting leukotriene C4 (LTC4) to leukotriene D4 (LTD4), both of which were found with an increment of concentration in menstrual blood from patients with primary dysmenorrhea ([@ref-32]) and the highly selective LTD4 receptor antagonist had an inhibiting effect on endometriotic implant growth in rat endometriosis model ([@ref-18]). However, our analysis also revealed that in the ectopic lesions, CYP2J2 was under-expressed, an enzyme of cytochrome P450 (CYP) superfamily to metabolize AA into EETs, which exerted an anti-inflammatory effect by various mechanisms ([@ref-36]). Taken together, the activated arachidonic acid (AA) metabolism and its corresponding products seemed to promote inflammation in ectopic lesions, thus facilitating the development of EMs.

Interestingly, the 5 hub nodes RRM2, AURKB, DTL, CCNB1, CCNB2 identified from the PPI network constructed by148 shared DEGs were all associated with cell cycle and mitosis, and down-regulated in the ectopic lesions in our analysis while always up-regulated in cancer tissues ([@ref-43]; [@ref-22]; [@ref-38]; [@ref-19]; [@ref-7]), thus promoting excessive proliferation, which suggested limited and controlled proliferative activity in EMs endometriotic lesions, distinct from cancerous proliferation feature. For example, RRM2, one of the subunits of ribonucleotide reductase complex providing precursors indispensable for DNA synthesis ([@ref-9]), was reported lowly expressed in EC compared to the EU in another genome-wide microarray study ([@ref-46]), while its overexpression would enhance tumor angiogenesis and growth in multiple cancers ([@ref-47]; [@ref-30]). AURKB, a chromosomal passenger protein ensuring correct chromosome alignment and segregation in the mitosis ([@ref-17]), was found low-expressed in OE ectopic tissues ([@ref-5]) whereas high-expressed in many tumors causing cell aneuploidy division ([@ref-11]). DTL, known as denticleless E3 ubiquitin-protein ligase homolog, was responsible for mediating the polyubiquitination and subsequent degradation of multiple regulators to ensure proper cell cycle progression ([@ref-15]), though seldom studied in EMs. However, the cyclin CCNB1, key regulator as well as CCNB2 in cell cycle controlling G2/M transition ([@ref-12]), were found up-regulated in ectopic tissue compared to eutopic endometrium in Tang et al. study ([@ref-40]), which was inconsistent with our analysis. This inconsistency might be explained by different detection methods and the intrinsic heterogeneity of EMs. Moreover, the phenomenon that most ectopic lesions contained sparse epithelial cells, which were abundant in eutopic endometrium and available to proliferate at a rapid speed, and mainly of stromal cells, whose multiplication rate was relatively mild, might result in the slow growth in ectopic tissue ([@ref-4]).

Moreover, besides the common pathogenesis, we also explored the peculiar molecular signature in each subtype of EMs by the KEGG analysis of specific DEGs in different subtypes. For instance, most genes in the pathway of ovarian steroidogenesis were significantly up-regulated in EC in subtype OE while with no significant difference between EU and EC in the PE and DIE, which suggested ectopic tissue specificity and focal prominent aberrant hormonal environment in OE. Furthermore, the most up-regulated gene STAR in the pathway was proved to be correlated with the severity of OE and PE ([@ref-41]). That OE was regarded as an indicator of more severe pelvic and intestinal disease ([@ref-31]) might be explained by this overactive ovarian steroidogenesis in OE since the steroid hormone was primarily produced in the ovarian and then reached endometriotic lesions via blood circulation and follicular fluid at the time of ovulation.

We also noticed that both specific DEGs in OE and DIE enriched in 'pathways in cancer', though enriched genes were different: DIE was associated with the risk of malignant transformation by enriched genes COL4A3, COL4A6, RAD51, F2R, PTGER3, while OE mainly by those PI3K pathway-related genes, such as FN1, GNG2, KIT, PTGS2, PDGFRA, LPAR1, CCND1, ITGA6, FGFR3, VEGFA, PIK3R1, FGFR2, MET. However, PE was more likely related to dysregulated peritoneal immune and inflammatory microenvironment, indicated by its specific DEGs enriched pathways, such as maladjusted cytokine-cytokine receptor interaction, leukocyte trans-endothelial migration, and natural killer cell-mediated cytotoxicity. Whether PE could be regarded as more 'superficial' or 'slight' disease primarily affected by peritoneal fluid factors, than OE and DIE mainly influenced by blood or ovarian factors ([@ref-23]), still needs further investigation. Hence, the landscape of specific signatures in each subtype were not clear enough in our analysis due to a relatively small number of available microarray datasets as well as limited information provided by these datasets, especially the DIE dataset based on a platform with fewer probes, which would be modified by obtaining more RNA-sequencing datasets including all three subtypes and considerable samples in future analysis.

However, our analysis still has some limitations. Firstly, due to the lack of RNA-sequencing datasets for PE and DIE, validation analysis was only performed in subtype OE. Secondly, since the uterine endometrium undergoes molecular signature changes throughout the menstrual cycle ([@ref-39]), different cycle phases might be one of the confounding factors: DIE samples were all collected during the proliferative phase, all PE samples and OE samples in [GSE7305](GSE7305) were collected during either proliferative or secretory phase, while cycle phases of OE samples in [GSE7307](GSE7307) were unknown. Comparing the gene expression in each subdivided cycle phase respectively would provide an improved perspective. Additionally, the contamination of normal tissue sometimes was unavoidable during the sampling process, which in a way would lead to potentially controversial results. For example, in our results, the significant overexpression of ovarian steroidogenesis related genes in OE while not in PE and DIE ectopic tissues may be explained by the intrinsic differences among subtypes and/or the mixture of normal ovarian tissues. This needs further laboratory investigation in the future.

Conclusion
==========

Through integrated bioinformatics analysis, we found that inflammation, especially arachidonic acid (AA) metabolism-related inflammatory process was the most common pathogenesis of OE, PE, and DIE. Besides, a slow and controlled proliferation in ectopic lesions was commonplace in these three EMs subtypes. Meanwhile, abnormal ovarian steroidogenesis was a prominent feature in OE; OE and DIE seemed to be at more risk of malignant development while PE tended to be more associated with dysregulated peritoneal immune and inflammatory microenvironment. All these findings could deepen our understanding of the common and specific molecular events in different subtypes in endometriosis.
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###### Clinical characteristics of patients with peritoneal endometriosis (PE) in [E-MTAB-694](E-MTAB-694)

Left to right: Patient I.D. (n=19), age in years (mean = 34.32 ± 7.6 years); stage of endometriosis peritoneal lesion according to the American Fertility Society \[AFS\] classification; menstrual cycle phase according to Materials and Methods in original article DOI: 10.1177/1933719112451147; tissues analyzed; (+, available; −, not available).

###### 

Click here for additional data file.
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###### Clinical characteristics of patients with Deep Infiltrating Endometriosis (DIE) in [GSE25628](GSE25628)

Left to right: Patient I.D. (n=8), age in years (mean = 31.5 ± 5.2 years); stage of endometriosis deep infiltrating lesion according to the American Fertility Society \[AFS\] classification; menstrual cycle phase according to Materials and Methods in original article DOI: 10.1002/jcp.24358; tissues analyzed; (+, available).

###### 

Click here for additional data file.
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###### All the significantly enriched KEGG pathways of 729 specific DEGs in OE

Abbreviations: Log2 FC, Log2 fold change; OE, ovarian endometriosis.

###### 

Click here for additional data file.
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###### The expression of genes enriched both in 'pathways in cancer' and 'PI3K-Akt signaling pathway' in OE in the microarray training dataset and RNA-sequencing validation dataset [GSE105764](GSE105764)

Abbreviations: Log2 FC, Log2 fold change; OE, ovarian endometriosis.

###### 

Click here for additional data file.
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###### Data preprocessing and normalization

(A), (B), (C), Boxplot of gene expression values after normalization in the merged OE dataset of [GSE7305](GSE7305) and [GSE7307](GSE7307), the individual PE dataset [E-MTAB-694](E-MTAB-694) and DIE dataset [GSE25628](GSE25628). Boxplots represent the mean ± interquartile range, with whiskers extending to the minimum and maximum value. The Abscissa axis represents samples; the vertical axis represents gene expression value; the black horizontal line represents the median of the gene expression value for each sample; the green boxes represent EU samples; the red boxes represent EC samples. OE, ovarian endometriosis; PE, peritoneal endometriosis; DIE, deep infiltrating endometriosis; EC, ectopic lesions; EU, eutopic endometrium.

###### 

Click here for additional data file.
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